Allogeneic stem cell transplantation (allo-SCT) is considered the cornerstone in the
treatment of several malignant and not malignant hematological diseases. However, relapse …

Donor lymphocyte infusion has been used in the management of relapsed hematologic
malignancies after allogeneic hematopoietic cell transplantation. It can eradicate minimal …

Donor lymphocyte infusions (DLI) often are used after allo-SCT to augment the graft-versus-
tumor effect. Timing of infusion varies according to indication, for example to treat tumor …

In order to study efficacy, toxicity and the long-term results of donor lymphocyte infusions
(DLI), we retrospectively analyzed DLI given for relapse after conventional allogeneic …

We treated 17 patients with refractory (n= 7) or relapsed lymphoid malignancy (n= 10)
following allogeneic HSCT with donor lymphocyte infusions (DLI). Patients with low-grade …

The impact of donor lymphocyte infusion (DLI) initial cell dose on its outcome is known in
patients with chronic myeloid leukemia but limited in patients with other hematological …

The role of donor lymphocyte infusion (DLI) in the management of lymphoid malignancies
after allogeneic stem cell transplantation (SCT) has not been clearly characterized. There is …

We evaluated the efficacy and toxicity of different doses of donor T cells given with donor
leukocyte infusions (DLI) as treatment for relapse of various hematologic malignancies after …

The efficacy and toxicity of donor leukocyte infusions (DLI) after unrelated donor bone
marrow transplantation (BMT) is largely unknown. We identified 58 recipients of unrelated …

Highlights•Donor lymphocyte infusion (DLI) provides a way to enhance the graft-versus-
leukemia effect.•GvHD represents the main toxicity after DLI.•Pre-DLI low disease burden …